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ABSTRACT
Co-occurrence of Flt3ITD and TET2 mutations provoke an animal model of AML 
by epigenetic repression of Wnt pathway antagonists, including RUNX3, and by 
hyperexpression of ID1, encoding Wnt agonist.  These affect HOXA over-expression 
and treatment resistance. A comparable epigenetic phenotype was identified among 
adult AML patients needing novel intervention. We chose combinations of targeted 
agents acting on distinct effectors, at the levels of both signal transduction and 
chromatin remodeling, in relapsed/refractory AML’s, including Flt3ITD+ve, described 
with a signature of repressed tumor suppressor genes, involving Wnt antagonist 
RUNX3, occurring along with ID1 and HOXA over-expressions. We tracked patient 
response to combination of Flt3/Raf inhibitor, Sorafenib, and Vorinostat, pan-histone 
deacetylase inhibitor, without or with added Bortezomib, in consecutive phase I 
trials.  A striking association of rapid objective remissions (near-complete, complete 
responses) was noted to accompany induced early pharmacodynamic changes within 
patient blasts in situ, involving these effectors, significantly linking RUNX3/Wnt 
antagonist de-repression (80%) and ID1 downregulation (85%), to a response, also 
preceded by profound HOXA9 repression. Response occurred in context of concurrent 
TET2 mutation/hypomorphy and Flt3ITD+ve mutation (83% of complete responses).  
Addition of Bortezomib to the combination was vital to attainment of complete 
response in Flt3ITD+ve cases exhibiting such Wnt pathway dysregulation. 
INTRODUCTION
Novel disease targets are necessary so as to improve 
acute myeloid leukemia (AML) patient outcomes, and 
epigenetic pathways are a focus.[1-3] We identified an 
oncogenic (Flt3ITD) pathway to epigenetic repression for 
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the tumor suppressor DAPK1, by interaction of p52NF-
κB and histone deacetylases (HDACs) on the promoter.
[4] Suboptimal efficacy of single Flt3-selective tyrosine 
kinase inhibitors (TKI) is thought to involve such 
epigenetic collaboration.[4-6] 
Wnt antagonist RUNX3 is a consequential 
epigenetically-repressed tumor suppressor gene in AML, 
especially normal karyotype (+/-Flt3ITD).[6-8] By such 
RUNX3 repression, its  function in interruption of Wnt/β-
catenin/TCF4-mediated transcription is prevented,[9] 
which allows β-catenin to promote leukemia stem 
cells,[10] by affecting HOXA10/9/CDX4 transcription.[11] 
RUNX3 was a prominent methylation-sensitive repression 
target of dual Flt3ITD/TET2 mutations in a murine AML 
model, and was repressed alongside BCL11b, another 
Wnt-β-catenin antagonist.[6] ID1 hyperexpression was 
also prominent in the signature along with HOXA9, and 
Id1 has been demonstrated a Wnt agonist.[6, 12] 
Poor-risk AML phenotypes, including Flt3ITD+ve, 
also express transcriptionally-active phospho-c-jun, 
affecting distinct gene activation.[13-18] C-jun acts with 
Stat5, in activation of transcriptional targets PIM1, relB, 
and MEIS1 (a prognostic gene functioning in leukemic 
stem cells).[15, 17, 18] Further, c-jun and β-catenin, 
reciprocally and cooperatively, bind the others promoter 
consensus, thus conveying cooperative transactivation, 
involving TCF4 elements such as regulate HOXAs.[11, 
19, 20] 
If not prevented by an epigenetic influence, the 
AP-1 family of proteins can also block cell cycle and 
promote senescence and apoptosis through transcriptional 
up-regulation of both DAPK1 and RUNX3, as well 
as p16INK4A/CDKN2A.[4, 7, 21, 22] Epigenetically 
repressed p16INK4A/CDKN2A promotes leukemia 
stem cell upregulation,[23] which is observed in normal 
karyotype Flt3ITD+ve and complex karyotype AMLs.[23] 
However, p16INK4A/CDKN2A repression is not observed 
in good-risk [eg. core-binding factor-associated (CBF+ve)] 
AMLs.[23-25]
We considered these tandem repressed tumor 
suppressor genes as candidates, among a group of 
prognostic genes, to form a signature for poor-risk AML 
vulnerable to an epigenetic targeting agent combination. 
We chose the Flt3/raf-selective tyrosine kinase inhibitor, 
Sorafenib, along with HDAC inhibitor, Vorinostat, given 
together as a doublet, or, additionally, in combination with 
epigenetically-active Bortezomib.[26-28]
We postulated that reversal, early during therapy, of 
such a blast cell gene expression signature, may predict 
an emerging remission, and may reflect an epigenetic 
reprogramming of poor-risk/refractory AML toward 
enhanced sensitivity, associated with non-expression of 
HOXA, which mimics core-binding factor translocation-
associated (CBF+ve) AML.[29]
While demonstrating the safety of two consecutive 
regimens, we compared the response rates and depth, as 
well as mechanistic attributes regulating responses. We 
found mechanistic signatures regulating achievement of 
remissions were uniform, but that Bortezomib addition 
had a dramatic impact on depth and rapidity of responses 
in Flt3ITD+ve, where early reversal of gene expression 
signature was predictive.
RESULTS
Response
Patient characteristics are summarized in 
Supplementary Information: Supplementary Tables 1-2. 
A total of 15 patients were enrolled in trial 1 with intent 
to treat (Supplementary Table 1). In the second trial, 18 
patients were enrolled (Supplementary Table 2). 
With the first cycle of treatment in trial 1 (Sor/Vor), 
six/fourteen (43%) patients demonstrated partial remission 
(PR) and 1/14 (7%) achieved a complete remission (CR) 
(Supplemental Table 1). The patient (#8) with complex 
karyotype who achieved a CR with one treatment cycle 
remained disease-free for 5 months (Supplementary Table 
1).
Three/six very good partial responders (# 5, 7, 14) 
and one marrow inevaluable patient (#9) had Flt3-ITD, 
with pre-treatment peripheral absolute blast counts as 
high as 50,000-85,000/uL, and all demonstrated complete 
clearance of peripheral blood blasts within 1 week of 
initiation of treatment (Supplementary Table 1). Following 
completion of 2 cycles, one responder in this group 
had reduction of marrow blasts to 10% accomanying a 
profound reduction of background cellularity.
Responses in the second trial (Sor/Vor/Bor), 
were generally more rapid, and complete morphologic 
eradication of blast cells occurred by 1-2 cycles in a 
significant fraction of patients with Flt3ITD, irrespective 
of the dose level beyond the run-in dosing of cohort 
1-where suboptimal Sorafenib was used to ensure safety 
(Supplementary Table 2). CR rate approximated 59% in 
that optimal Sorafenib dosing group (Supplementary Table 
2).
Initial gene expression analysis defines repressed 
tumor suppressor signature in AML blasts 
Poor prognosis occurs in AML patients whose 
blasts exhibit repressed expressions of p16INK4A/
CDKN2A and DAPK1, on a background of HOXA9/
MEIS1 over-expression (HS Boswell, unpublished data).
[4, 23] These features coincide with ID1 hyperexpression, 
which overlaps with these repressed genes, and repressed 
RUNX3.[30] Therefore, we performed focused gene 
expression analysis on available pretreatment blasts from 
patients on the first trial, as test cohort (Figure 1).
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Compared with the good-risk (CBF+ve) gene 
expression control panel, where p16INK4A/CDKN2A is 
not repressed [23] (Figure 1; data not shown), all these 
patients’ blasts demonstrated strong over-expression of 
HOXA9/MEIS1 on the heat-map, accompanying CDKN2A 
repression. In addition, ID1 hyper-expression was noted 
in a subgroup of patients (#6, 7, 8, 11, 13, and 14), where 
its hyper-expression overlapped with repressed CDKN2A/
DAPK1, and in most cases, repressed RUNX3 (Figure 1). 
In trial 1, Sorafenib/Vorinostat promoted changes 
in Flt3ITD+ve blasts for expression of genes and 
effector proteins leading to ER stress apoptosis
Because of the slower/lower depth of/ response to 
the initial regimen (Sor/Vor), an association of changes 
between gene expression with phosphoprotein signaling 
intermediates upstream was possible. Immunoblot analysis 
was performed on pre-treatment blasts with sufficient 
content: normal karyotype Flt3-ITD+ve patients #7 vs. #9, 
which accurately demonstrated the heterogeneity expected 
for activity and subcellular localization of phospho-
intermediates based on the gene expression analysis 
(Figure 2a vs. Figure 1). 
Upon initiation of therapy in patient #7 at day #3, 
where the marrow was still replete with blasts, strong 
reductions within lysates of nuclear phospho-c-jun (70% 
reduction by densitometry: Figure 2a and 2d), p52NF-κB 
(70% reduction: Figure 2a and 2d), and phospho-stat5 
(80% reduction: Figure 2c) occurred, and re-localization 
of stat5 and p52 NF-κB into the inactive cytoplasmic 
pool was observed (Figure 2a and 2c). However, neither 
Figure 1: Repression of Tumor Suppressor genes accompanies overexpression of HOXA/MEIS1. Focused GSA (gene set 
array) expression profile prior to therapy (day 0) of patients treated on first (IUCRO-0234) protocol identifies a group with repression of 
DAPK1/CDKN2A/RUNX3 and co-existing ID1 hyperexpression (note blue bracket) as compared with a control CBF+ve AML with good 
prognosis. Presented on the horizontal axis, left-to-right, are patients # 7, 8, 14, 6, 11, CBF+ve control, 13, and 9, respectively. Patient 
#5 had insufficient blast content to perform gene expression analysis prior to therapy, but upon discontinuation of protocol therapy, with 
disease progression, demonstrated the same phenotype of repression as the bracketed group (data not shown).
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DAPK1 nor CDKN2A mRNAs were de-repressed (Figure 
2e); nevertheless, the multi-responsive p52NF-κB/stat5/c-
jun-dependent PIM1 and PIM2 genes were diminished 
(p<0.08 and *p<0.05, respectively), and the stat5/c-jun-
dependent ID1 transcripts were reduced by almost 2 
logs (Figure 2e, ***p<0.0002). [A day 3 protein analyte 
was not available from patient #9.] We also observed 
relocalization of Flt3 to a surface/inactive pool, associated 
with manifestations expected of ER stress apoptosis upon 
PIM kinase loss (and 4EBP1 reregulation) in patient #7 
lysates[31] (Figure 2b). 
The genes whose expression was most significantly 
decreased in the early-phase of therapy in the marrow 
blasts of patient #7 were JUN, MEIS1 and ID1 (***p< 
0.00002, ***p<0.00003, and ***p<0.0002, respectively) 
(Figure 2e). Interestingly, the strong reduction of 
peripheral blood and bone marrow blasts that followed 
(Supplementary Table 1) was also preceded by sharp 
HOXA9/10 downregulation in day #3 blasts (**p<0.05, 
***p<0.005, respectively) (Figure 2e). RUNX3 (not 
shown) was not de-repressed in this patient’s blasts, 
perhaps because c-jun/JUN (a transactivator of RUNX3, 
DAPK1, and HOXA10) was so strongly expressed initially, 
and then extinguished by treatment.
Normal karyotype Flt3ITD+ve patient #14, whose 
blast gene expression heat-map similarly revealed 
the triple-repressed tumor suppressor gene signature 
noted above (Figure 1), was pharmacodynamically 
monitored with therapy, which demonstrated a different 
mechanistic complement and a distinct route to an ER 
Figure 2: Flt3ITD AML responds to Sor/Vor with strong downmodulation of HOXA’s and MEIS1 accompanying 
profile of ER stress apoptosis. Activity by starting levels: intranuclear p52 NFkB in #7 and #9, 59% and 26%, respectively; phospho-
stat5, 78% in #7. These corresponded to higher level of immuno-detected p-jun in #7 and also a lower DAPK1 protein in #7, which would 
be expected of a cause-and-effect relationship with p52 NFkB- a known DAPK1 repressor. (a to d) Sorafenib and vorinostat-induced 
remission in patient #7 is associated with induction of ER stress apoptosis pathway (Flt3 relocalization, elevated IRE1α, cleavage (70% 
densitometric) of procaspase 4) despite failure to upregulate low-level expression of DAPK1. However, both p52NFkB and phospho-stat5, 
which also drive transcriptional expression of PIM1/2 were severely depleted, leading to an alternative route to ER stress apoptosis. C 
stands for cytosolic fraction and N stands for nuclear fraction. Molecular weights in the immunoblots are indicated. (e) The remission in 
patient #7 was also associated with severe reduction of JUN and ID1 transcripts, as well as MEIS1 and PIM2 transcripts, and significant 
depletion of HOXA10/9 transcripts. However, CDKN2A transcripts were not augmented in this case. Molecular weights in the immunoblots 
are indicated.
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stress apoptotic outcome in blasts, independent of PIMs 
(Figure 3). A dramatic response to Sor/Vor therapy ensued 
(Supplementary Table 1). Pre-treatment marrow blasts 
demonstrated significant, but more limiting, intranuclear 
levels (vs. #7 (Figure 2)) of phospho-stat5 and p52NF-κB 
(Figure 3a, left panel). At treatment day #4, nuclear lysates 
of blasts revealed total loss of p-stat5, and significant 
reduction of p52NF-κB (65% reduction by densitometry). 
This occurred in the setting of 5-fold up-regulation of 
DAPK1 transcripts by real-time qRT-PCR (*p<0.04) 
and stable DAPK1 protein levels, along with 3-fold up-
regulation of CHOP (Figure 3a, left panel). Expected ER 
stress apoptosis evolution in blasts was further evidenced 
by Caspase 4 cleavage (>80% by densitometry) (Figure 
3a, right panel). Indeed, this apoptotic process occurred in 
the absence of downregulation for PIMs, whose starting 
expression was quite low in context of low starting levels 
of p-jun and p52NF-κB vs. patient #7 (Figure 2 and data 
not shown). 
In addition, the starting expression of HOXA’s was 
much lower here, in keeping with modest levels of JUN 
(<200-fold less JUN than patient #7) as driver, affecting an 
absent p-jun band visible by immunoblot (data not shown). 
The 8-fold up-regulation of RUNX3 transcripts observed 
by real-time qRT-PCR (**p<0.006) (Figure 3b) was not 
associated with any change in putative target. There 
Figure 3: Upregulation of DAPK1/RUNX3/CDKN2A presages remission following evolution of ER stress apoptosis. 
(a) A patient with normal karyotype, Flt3ITD (#14) at pretreatment evaluation demonstrated by immunoblot strong activation of phospho-
active stat5 and p52NFkB as well as having strong repression (compared to CBF+ve control AML) CDKN2A, and DAPK1, as well as lesser 
repression of RUNX3. Early evidence for evolving remission after 3 days demonstrated by immunoblot involved strong upregulation of 
CHOP, cleavage of caspase 4 (80% densitometric) evidencing ER stress apoptosis occuring in context of strong depletion of stat5/p52NFkB 
activation. Molecular weights in the immunoblots are indicated. (b) In addition, upregulation of transcripts for DAPK1, CDKN2A and 
RUNX3 were demonstrated.
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was derepression in CDKN2A transcripts of borderline 
significance (p=0.07), and no change in ID1 expression 
(Figure 3b; and data not shown). 
Thus, the mechanism to effect apoptosis in these 
Flt3ITD+ blasts was distinct from those Flt3ITD+ blasts 
patient #7, and the de-repression of DAPK1 observed 
here appears to result from the inhibition of the repressive 
influence of p52NF-κB with HDACs.[4] 
On the other hand, patient #6 without Flt3ITD, 
enrolled into dose-level 2 with optimal Sorafenib dosing 
and proven Vorinostat pharmacodynamics,[32] did not 
respond (Supplementary Table 1). We found failure to 
reduce baseline nuclear p52NF-κB levels, rising p65NF-
κB levels, and rising, extremely high HOXA9/MEIS1 at 
day 4 (data not shown), supporting the importance of the 
predictive findings. 
Evidence for activity of the Sor/Vor drug 
combination was also present among cases with 
complex/poor-risk cytogenetics (Supplementary Table 
1), where CDKN2A repression is well described.[23, 
33] Pretreatment blasts patient #8 demonstrated strong 
CDKN2A repression and ID1 hyperexpression (Figure 1), 
and early with therapy an early 3-fold log-reduction of 
ID1 transcripts (**p<0.01) and an elevation of CDKN2A 
Figure 4: Coupling of RUNX3 upregulation and/or ID1 downregulation along with HOXA reductions early after 
Sor/Vor/Bor leading to remissions. Transcriptional changes induced by combination of Sor/Vor/Bor regimen in patients, comparing 
pretreatment marrow blasts with day3/4. Patient #5 had total reduction of ID1 transcripts and significant upregulation of RUNX3 following 
initiation of therapy. The same outcome was seen in patient #13. Patient #6 had severe reduction of PIM1 as well as ID1 transcripts upon 
initiation of therapy. The most common result for responses was severe depletion of ID1 and upregulation of RUNX3, associated with 
HOXA9/10 depletion. TET2 transcript hypomorphy was strongly associated with these outcomes (Supplementary Table 3).
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transcripts of at least 2-logarithms (***p<0.003) occurred 
(data not shown). 
Dramatic increase occurs in depth and rapidity 
of responses in Flt3ITD+ve disease by addition of 
Bortezomib, involving ID1/RUNX3/HOXA axis.
In the second trial including Bortezomib, responses 
were seen beginning at cohort 2 (which involved 
resumption of Sorafenib at efficacious single-agent dosing 
and schedule) (Supplementary Table 2). These responses 
demonstrated no association to level of Bortezmib 
escalation in dose or schedule. Nor did responses relate to 
resumption of the full schedule of Vorinostat, as achieved 
in the prior protocol (Supplementary Tables 1, 2). 
However, responses were limited to Flt3ITD+ve patients 
(Supplementary Table 2). 
Eradication of peripheral blasts was hastened, and 
marrow cellularity at day 4 was too limiting to allow 
immunoblotting analyses. However, gene expression from 
marrow blasts (day0/4) was quite informative, and relayed 
the previous trends, particularly in the HOXA/RUNX3/ID1 
axis (Figure 4). 
Among patients in cohort 2 (dose-level 1) 
(Supplementary Table 2), strong HOXA9 and HOXA10 
expressions in the pretreatment blasts were sharply log-
reduced or extinguished early into therapy at day 4, 
when a subsequent CRi later evolved (HOXA9: patient 
#5, **p<0.01; patient #6, *p<0.05; HOXA10: pt#5, 
*p<0.05, pt#6, **p<0.01) (Figure 4). On the other hand, 
no such reductions occurred in non-responding patients, 
or in patient #12 with a PR achieved with the 1st cycle 
that did not improve with cycle #2 (Figure 4a). In the 
CRi responders (#13 and #17) in cohorts 4 and 5, HOXA 
expression and MEIS1 expression were limiting to begin 
with (Figure 4a), perhaps related to the much lower c-jun 
activity capable of driving HOXAs/MEIS1 than in the 
aforementioned cases, similar to the situation that obtained 
with patient #14 in trial 1 (Supplementary Table 1, Figure 
3). 
In the CRi responders, response was heralded 
in blasts by early sharp downregulation of ID1 (pt #5, 
***p<0.005; pt #6,**p<0.005; pt# 13, **p<0.005, pt# 
17, *p<0.05) (Figure 4b). In all of the blasts of CR/CRi 
responders, including the CR from the first trial (5/5), 
ID1 was sharply downregulated early by therapy (Figure 
4b and Supplementary Table 3) (p<0.002 compared with 
PR/nonresponders). In all but two of patients with CR/
CRi/VGPR achieved across both trials, early RUNX3 
upregulation in blasts (5/7) was associated with that 
response (Figure 4b, Figures 2-4, Supplementary Table 
3), and in those outlier cases, sharp downregulation of 
JUN/cjun, a HOX/MEIS1 transactivator, occurred as 
an alternate route to the endpoint (#7, trial 1, #6, trial 
2[data not shown]). In the latter example (trial 2, patient 
#6), absent RUNX3 upregulation, PIM1 downregulation 
as well as ID1 downregulation was noted in association 
with response (Figure 4). None of the patients’ blasts 
attaining CRi in the second trial demonstrated significant 
CDKN2A upregulation, whereas both the VGPR#14 and 
CR#8 in trial #1, upregulation of CDKN2A occurred 
(Supplementary Table 3). 
Induced ID1 hypo-expression occurred in 4/4 
CR/CRi’s and 5/6 VGPR/CR/CRi and was associated 
with both RUNX3 de-repression/upregulation, HOXA 
diminution and CDKN2A de-repression. However, absent 
VGPR/CR/CRi, ID1 depletion did not occur (p<0.002). 
Vulnerability of Flt3ITD+ve AML with TET2 loss 
and heightened HOXA’s 
Haploinsufficient mutations of TET2 gene, as well 
as miRNAs targeting 5’-3’ destruction of its mRNA, affect 
epigenetic functions.[34-36] In either case, functional 
transcript reduction ≥35% yields a hypomorphic 
phenotype; affecting repression of Wnt pathway 
antagonists, which are WT1 target genes. [1, 6, 13, 25, 37, 
38] Poor clinical outcomes result.[39] 
We postulated poor outcome might be linked to 
RUNX3 repression, in part, through heightened HOXA 
signaling (as consequence of unrestrained β-catenin[9]). 
Available blast cells from our two trials were analyzed 
for existence of truncated/mutant TET2 mRNAs 
(failed elongation/detection occurs with common 
nonsense/frameshift mutation) as well as reduction of 
complete transcripts by antagonistic miRNA’s (Figure 
5, Supplementary Table 3). We stratified samples in 
comparison to the same CBF+ve controls as before 
(because TET2 mutation is not associated with inv(16) 
CBF AML:(4) TCGA database <2%), and placed a 
distinction between samples with more or less than 65% 
of the high-expressor controls for TET2 transcripts to 
distinguish a hypomorphic phenotype.
TET2 transcript deficiency of starting blasts signaled 
enhanced activity of the combinations, especially Sor/
Vor/Bor (Figure 5). This was noted by severe reduction 
(or ablation) of the 3’/5’ transcript ratio (corresponding 
mutation) in the pretreatment blasts of majority responders, 
especially in the second trial (Figure 5). Proper assignment 
was confirmed with independent primers in the TaqMan 
plate (data not shown). In addition, preexisting blast TET2 
hypomorphy most commonly associated with RUNX3 
derepression upon initiation of therapy (Supplementary 
Table 3). Among 15 samples across both trials available 
for multigene molecular analysis, early relief of RUNX3 
repression occurred in 8/10 responders (5/7 CR/CRi/
VGPR), whereas 2/3 non-responders with samples 
available for analysis failed to demonstrate RUNX3 de-
repression (p=0.03, Chi square). 
RUNX3 de-repression and/or JUN/c-jun 
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downregulation was linked to early treatment-induced 
diminution of HOXA9/10 expression in blasts and 
subsequent hematologic response (Supplementary Table 
3). As noted above, this was also associated with early 
ID1 hypo-expression, while induced along with HOXA 
diminution. Thus, a pathway of epigenetic repression was 
alleviated by the combination therapy involving signature 
ID1-TET2-RUNX3, and HOXA depletion was linked to 
modulation of this pathway and JUN/c-jun.
DISCUSSION
AML relapse/resistance after therapy may be 
epigenetically determined. Mutant epigenetic modifiers 
that may persist in remission and contribute to relapse 
are mDNMT3A, mASXL1, mTET2. As a consequence, at 
least in the first two genes, hypomethylation on HOXA 
alleles, and resultant HOXA hyperexpression occurs.[40-
42] By contrast, good risk CBF +ve AMLs, which display 
highly durable induction/consolidation chemotherapy 
outcomes, display severe HOXA/B hypoexpression within 
bulk and CD34+ cells, in association with leukemic stem 
cell content of limited depth.[24, 29] Thus, modulation 
of chemosensitivity may require diminution of the 
chemoresistance effector and LSC driving factor HOXA9. 
[11, 24, 43]
Here, we investigated the impact of TET2 
hypomorphy on a putative pathway to affect unrestrained 
HOXA overexpression, which may be a consequence 
of repression in RUNX3- an inhibitor of HOXA driver 
β-catenin. We postulated AMLs with this signature 
might be affected by an epigenetically-active targeting 
combination given to patients. In addition, we postulated 
recognized positive regulators of the pathway to HOXAs: 
c-jun and Id1, may be sensitive to the combination.[11, 
19, 20] 
Combined administration of Sorafenib and 
Vorinostat, especially along with Bortezomib, induced 
rapid and deep remissions in patients Flt3ITD+ve, 
commonly characterized by early limitation of blast 
HOXA’s expression. Such induced remissions were 
accompanied in 80% cases with upregulation of 
repressed RUNX3, and were also strictly linked to ID1 
downregulation. Reversal of the epigenetic signature 
by the targeting combination appears to signal mutual 
involvement of members in leukemic genesis as 
Figure 5: Mutant TET2 marks response to Sor/Vor or Sor/Vor/Bor. TET2 transcript relative quantity was plotted in comparison 
to CBF+ve control for the two trials, distinguishing responders vs. nonresponders. Mutant transcript profile was defined as quantity of 
3’/5’ transcript quantity equal to or less than 0.65x control, whereas non-mutant transcript quantities were defined based on conventional 
detection methods.
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observed in a mouse model,[6] and signature reversal 
was a descriptor of subsequent remission. However, 
because RNAseq and/or protein interaction studies were 
not performed here, conclusive assignment of a direct 
converging pathway cannot be made.
Introduction of Bortezomib within the regimen 
sharply increased rapidity and depth of response to the 
combination in Flt3ITD+ve cases, and Bortezomib 
has demonstrated effect on transcriptional and 
posttranscriptional inactivation of Flt3.[26-28] Bortezomib 
was also found by others to downregulate HOXA9 in 
human Flt3ITD AML cells, while sensitizing the cells 
to chemotherapies and TKIs, which involved an induced 
repression of HOXA9, by rescue from proteasomal 
destruction of histone H3 K27 methylator- EZH2, the 
enzymatic effector of polycomb repressive complex 2.[43] 
In the Flt3ITD+ve cohort treated with the Bortezomib 
combination, there were insufficient blast cells at day 
¾ to address these issues fully, as a direct result of the 
activity of the combination. However, we previously 
tested Bortezomib with and without TKI in vitro on 
other genotypically similar Flt3ITD+ve AMLs, and 
demonstrated sharp Flt3 protein loss within cell lysates 
with short treatment. On the other hand, in our trial we did 
analyze EZH2 mRNA before and at day ¾ of treatment in 
situ without a clear predictive level of EZH2 transcripts 
at these timepoints for determining subsequent response.
Thus, Sor/Vor/Bor is a novel combination with 
promise for priming poor-risk AMLs with this gene 
expression signature, particularly Flt3ITD+ve with 
TET2 mutation, for subsequent therapeutic sensitization 
(Supplementary Table 3). Indeed, the capacity for this 
regimen to be a bridge-to-transplant with prolonged 
subsequent disease-free survival was demonstrated, 
and additionally another patient with reversal of this 
gene signature anticipating the induced remission, had a 
5-month unmaintained remission. 
We found no evidence for an influence on 
responsiveness for one accompanying gene mutation 
frequently occurring with Flt3ITD: mutant NPM1 (data 
not shown). Recently, patient blasts, documented by 
NGS as bearing complements of Flt3ITD with IDH2/
WT1/TET2/DNMT3A mutations (when alone or in 
mutually nonexclusive pairs), were also tested in vitro 
for proliferative silencing /apoptosis by Bortezomib 
with Flt3 inhibitor, and we found efficacy and synergy 
of the combination in these mutational binary- or 
ternary-defined subgroups in Flt3ITD+ve AML (HS 
Boswell, in preparation). In fact, because of the strict 
association at diagnosis, and stability upon relapse, of 
essentially all Flt3mutant AML’s with accompanying 
epigenetic mutations within IDH2/TET2/WT1 pathway 
or, additionally, with DNMT3A or ASXL1 mutations, 
this regimen, or a very similar one, may have broad 
applicability for sensitivity “priming” [43,44]. 
Our study performed in-depth examination of the 
early changed protein/gene signature achieved in situ 
within blast cells toward crucial downstream effectors, 
which revealed significant differences from the mechanism 
anticipated from Flt3-selective TKI alone. [4, 45, 46] Our 
data demonstrated, for at least Flt3ITD+ve/TET2mut/
hypomorphic AML, a more complex and cooperative 
remission-inducing mitigation, by epigenetic combinations 
causing de-repression/upregulation of Wnt antagonist 
RUNX3, and affecting severe ID1 and JUN/c-jun 
depletion, which were associated with HOXA depletion.[6, 
9, 12, 20] By contrast, mechanistic linkage to CDKN2A/
DAPK1 de-repression was infrequent. 
MATERIALS AND METHODS
Patient selection
In the first trial, all adult patients with a diagnosis 
of relapsed or refractory AML, and those older than 
70 with newly diagnosed disease, were eligible upon 
informed consent (Supplemental Information), adequate 
performance status and hepatic/renal function. In the 
second trial (Supp. Inf.), patient selection was restricted 
to Flt3ITD+ve, or complex karyotype or monosomy 5/7, 
from relapsed/refractory patients across the age spectrum, 
or additionally, from newly diagnosed elderly. All patients 
had a baseline bone marrow aspiration for staging/
diagnosis and pharmacodynamic studies (baseline) as well 
as cytogenetics and Flt3 mutation analysis.
Trial designs and treatment
A conventional 3+3 dose-escalation schedule was 
followed with 3-6 patients per cohort. The dose-escalation 
schemes for trial 1 are noted under Supplementary Table 
1. Sorafenib was given orally at a dose of 400 mg twice 
daily, and oral vorinostat was given with dose escalation 
in successive cohorts. Each cycle consisted of 14 days of 
treatment followed by 7 days of break, 21 days total. A 
bone marrow exam for response evaluation was performed 
on day 15 of each cycle. Response was assessed as 
reported by Cheson.[47] Patients who achieved at least 
50% reduction of bone marrow blasts to 5-25%, but 
not a complete morphologic remission, were eligible 
to receive the second cycle. Patients, who achieved at 
least 10% reduction of bone marrow blasts, but not a 
complete remission with the second cycle, were eligible 
for a third cycle. Patients received a maximum of 3 cycles 
in this first trial. No further treatment would be given 
beyond a complete remission (CR). The dose-limiting 
toxicity (DLT) was defined as any grade 3 or 4 non-
hematologic toxicity using the National Cancer Institute 
NCI’s Common Terminology Criteria for Adverse Events 
(CTCAEv3.0). 
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In the second trial a similar 3+3 design was used 
(Supplementary Table 2), but the initial schedule involved 
dose-reduction of Sorafenib to 200mg po bid to avoid 
possible toxicity associated with addition of a third drug-
Bortezomib. This dose level assigned within cohort 1 was 
deemed run-in (-1) dosing. Also, dosing with Vorinostat 
was initially reduced in schedule, but not in dose, from 
optimal schedule in protocol I, to days 1-4, and 8-12, to 
avoid potential toxicities associated with initiation of the 
3rd drug-Bortezomib. No such toxicities were observed, 
and a 5th dosing level including Sorafenib and Vorinostat, 
at the full schedule from the first trial, were still 
compatible with the optimal dose-schedule of Bortezomib 
(Supplementary Table 2).
Cells
Bone marrow blast cells were obtained from patients 
within 7 days prior to treatment and at the end of 3-4 days 
of therapy, and processed as previously described.[4]
Real-time RT PCR analysis in a focused gene-set 
array panel
This was as described.[4] qRT-PCR for 30 
AML related genes and one housekeeping gene were 
performed at low-density array (LDA) format according 
to the manufacturer’s protocol (TaqMan Gene Expression 
Micro Fluidic card, 4346799, Applied Biosystems/Life 
Technologies). 18S rRNA was chosen from TaqMan 
Human Endogenous Control Plate (Applied Biosystems) 
as internal control. Relative expression was calculated 
using RQ manager Ver 1.2 (Applied Biosystems) using 
one-patient volunteer as a calibrator sample (fusion core-
binding factor-positive (CBF+ve[inv(16)]), negative for 
Flt3ITD, and very low c-jun and Meis-1 expression). In 
addition, the CBF+ve control had high expression of TET2 
mRNA, as expected based on the rarity of TET2 mutation 
within this good-risk AML subgroup (see below). Copy 
number or fold-change in expression was calculated using 
the 2-∆∆Ct method.[48] For initial definition of a tumor 
suppressor gene “repression cohort” among the group 
of patients accrued to the trial with intention-to-treat, 
baseline expression data of 29 test genes was normalized 
to expression of c-jun, which is a known trans-activator of 
the core tumor suppressor target gene cohort (CDKN2A, 
DAPK1, RUNX3), and MEIS1.[4] Data were conveyed 
into heat-map format reporting ∆CT values and statistical 
analysis was applied to these values, using 18S RNA as 
control value.
Real-time RT-PCR analysis of TET2 expression
Two real-time PCR primer pairs were 
designed to amplify the 5’ (497-591bp) and 3’ 
(6127-6238bp) part of human TET2 mRNA 
respectively. The sequences are: TET2-5’ forward: 
5-GATAGAACCAACCATGTTGAGGG, TET2-5’ 
reverse: 5-TGGAGCTTTGTAGCCAGAGGT, TET2-
3’ forward: 5-GCATGCCACAACCCCTTTAA and 
TET2-3’ reverse: 5-CCAAAGAGCCAAGCCATGTT. 
Expression of the 5’ and 3’ part of TET2 mRNA was 
first normalized by GAPDH expression and then the 
expression ratio of 3’ mRNA to 5’ mRNA was calculated 
using 2-ddCt method. GAPDH primer sequences are: 
forward: 5-GACCACAGTCCATGCCATCACT and 
reverse: 5-GCTTCACCACCTTCTTGATGTCA. Data 
for transcripts detected with an updated microfluidic card 
including TET2 were obtained in the second cohort, and 
analyzed by the aforementioned protocol.
Immunoblot analysis
Cytosolic or nuclear proteins were subjected to 
Western blotting with indicated antibodies as described.[4] 
Statistical analysis
Individual patient gene expression data within the 
defined cohorts was subjected to population analysis 
for statistical distinction using Mann- Whitney/Wilcox 
methodology and reported as p value for null hypothesis at 
95% confidence interval. Additionally, t-test methodology 
was also used for comparison of individual patient 
samples for distinction of gene expression change upon 
patient treatment.
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